
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne is attractive because its QCT platform and single-molecule quantification create differentiated prenatal and oncology assays that address real workflow pain points, including UNITY’s one-blood-draw fetal risk screening and Northstar’s ultrasensitive liquid biopsy capabilities. Fundamentally, the company is converting that technology edge into commercial traction, with Q1'26 revenue of $108.4M (+84% Y/Y), 73% gross margin, 16% GAAP operating margin, $537M of cash, and total payer coverage reaching ~300M lives after Anthem and UnitedHealthcare wins. The positive outlook is further supported by conservative guidance that still calls for 2026 revenue of $450M-$465M and 70%+ gross margins, while new launches like UNITY Confirm and the planned MRD test expand the runway across very large prenatal and oncology markets.
Bears say
BillionToOne is facing a weaker fundamental setup because Q2'26 showed solid 64% revenue growth to $109.4M, but operating expenses surged 59% to $72M as management pulled forward sales hiring, causing Adj. EBITDA of $16.1M and GAAP EPS of $0.15 to miss expectations. Despite $549M of cash and positive $5.1M FCF, the company reaffirmed 2026 revenue guidance of $450M-$465M while forecasts for 2026-2028 were cut, with higher opex and only modest gross margin support limiting leverage. The bearish view is further supported by dependence on complex reimbursement and billing processes, concentration in molecular diagnostics, and uncertainty around how durable UNITY’s ~15% prenatal market share and newer oncology products will be against competition and execution risk.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares